TLSA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 22:23):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
今日成交量	71 400.00
平均成交量	198 846
市值	81.99M
EPS	$0 ( 2024-04-22 )
下一个收益日期	( $0 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.68
ATR14	$0.0110 (1.38%)

音量相关性

長: 0.25 (neutral)

短: -0.34 (neutral)

Signal:(51.937) Neutral

Tiziana Life Sciences PLC 相关性

10 最正相关

10 最负相关
FITBP	-0.876
ACGLN	-0.87
PFF	-0.853
ENLV	-0.842
RCEL	-0.838
JSM	-0.837
ADSK	-0.827
FITBO	-0.814
FTXH	-0.811
BJK	-0.806

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tiziana Life Sciences PLC 相关性 - 货币/商品

0.34
( neutral )

0.47
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

-0.60
( weak negative )

Tiziana Life Sciences PLC 财务报表

Annual	2022
营收:	$0
毛利润:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2022
营收:	$0
毛利润:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.139

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Tiziana Life Sciences PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.